Connecting to Grow: Why Shared Insight and Strategic Relationships Are the Most Efficient Path Forward in Biotech

03 Jun 2026

By Amanda Keightley-Pugh, Chief Commercial Officer, LBIC

In today’s life sciences landscape, capital remains important, but it is no longer the defining factor of success. What I consistently see is the companies that move fastest and most efficiently are not always those with the largest funding rounds, but those that are best connected: to insight, to expertise, and to the right conversations at the right time.

As the funding environment becomes more selective, this shift has become even more pronounced. Founders are under increasing pressure to make early decisions count, preserve runway, and deliver meaningful progress with fewer resources. In this context, how a company learns and who it learns from has become a critical determinant of success.

The Power of Shared Learning

Across the sector, there is growing recognition that shared learning is one of the most cost-effective tools available. Access to people who have already navigated similar scientific, commercial, or regulatory challenges can dramatically change the quality and speed of decision-making.

Experience shows that all too often, early-stage companies try to solve complex problems in isolation only to discover later that others have faced and overcome the same challenges. This can lead to avoidable delays, unnecessary spend, and strategic missteps that could have been mitigated through earlier input.

By contrast, in practice when founders engage openly with investors, advisers, and peers, they are able to:

• Pressure-test assumptions before committing significant capital
• Identify more efficient development pathways
• Avoid duplicating effort already undertaken elsewhere in the ecosystem
• Make clearer, more confident decisions at critical inflection points

In practical terms, this means that shared experience can directly extend runway and accelerate progress. It’s become clear to me that this combination is particularly valuable in a capital-constrained market.

Why Proximity Still Matters

While digital connectivity has made information more accessible, what I’ve observed is physical proximity within a well-connected ecosystem continues to play a unique and powerful role.

When companies operate in close proximity to investors, researchers, clinicians, and other founders, the barriers to meaningful interaction are significantly reduced. Conversations that might otherwise take months to arrange can happen informally, and often more productively, through day-to-day engagement.

These interactions may appear small or incidental, but they are often where the most valuable exchanges happen. A brief discussion can lead to a new perspective on a scientific approach, an introduction to a potential partner, or early insight that prevents a costly mistake.

This is why leading global organisations are increasingly choosing to embed themselves within established clusters. They recognise that innovation is not just driven by infrastructure or funding, but by the density and quality of relationships within an ecosystem.

Collaboration in Practice

Across London and the wider UK life sciences cluster, many of the most successful outcomes have been shaped by collaboration. Looking across the sector, these examples reinforce a consistent principle: progress accelerates when expertise is shared.

Partnerships between academia and industry continue to play a vital role in translating discovery into real-world impact. Collaborations between emerging biotech companies and larger organisations enable access to capabilities and expertise. Whether as simple as access to complex bioanalysis equipment, insights from those experienced in clinical development, etc, that would be difficult and costly to build independently.

Equally, peer-to-peer exchange between founders is often underestimated. Some of the most valuable insights come not from formal advisory settings, but from conversations with others who are navigating similar challenges in real time.

Experience shows that what these different forms of collaboration have in common is their ability to reduce risk, increase efficiency, and accelerate learning cycles. They enable companies to move forward with greater clarity and confidence, while helping to preserve precious resources.

From Connection to Impact

For companies operating in a sector defined by long timelines and high complexity, the importance of connection cannot be overstated. Across the companies that I work with the most effective are those that actively build and engage with their networks from the earliest stages.

This is not simply about increasing visibility. Today, it is about ensuring access to the right perspectives when decisions matter most. The ability to draw on collective insight allows founders to move more strategically, adapting quickly as new information emerges.

It also creates a more resilient route to growth. One thing that stands out to me is companies that are well-connected are better positioned to identify opportunities, secure partnerships, and respond to challenges as they arise.

Enabling More Efficient Growth

This is where facilitated environments play an important role. At LBIC, I see our role not as the centre of the story, but as a connector charged with creating the conditions where these interactions can happen naturally and consistently.

In my experience, it is not the events or programmes themselves that create value, but what they enable:

• The exchange of knowledge between founders, investors, and advisers
• The formation of relationships that can evolve into partnerships
• The sharing of experience that helps companies avoid costly missteps
• The acceleration of learning across the ecosystem

Whether through structured roundtables or informal conversations, the objective is the same: to ensure that companies are not navigating complex challenges alone but are supported by the collective insight of the community around them.

A More Connected Path Forward

The message for the life sciences sector is clear. In a more selective funding environment, efficiency is no longer just about doing more with less, the pressure is on to learn faster and make better decisions earlier.

Across the ecosystem, the companies that succeed are those that recognise this early and act on it. They prioritise connection, seek out diverse perspectives, and actively engage with the ecosystems around them.

Because ultimately, the most efficient way to build a biotech company is to move forward, faster, together.